Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight
NEW YORK, December 31, 2025, 18:50 ET — After-hours
- Pfizer shares slipped in extended trading as investors weighed fresh U.S. drug-pricing headlines.
- The company is at the center of a new round of list-price changes scheduled for 2026.
- Traders are watching for January pricing updates and Pfizer’s next results briefing.
Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really…
